High resolution melting for mutation scanning of TP53 exons 5-8

被引:112
|
作者
Krypuy, Michael
Ahmed, Ahmed Ashour
Etemadmoghadam, Dariush
Hyland, Sarah J.
deFazio, Anna
Fox, Stephen B.
Brenton, James D.
Bowtell, David D.
Dobrovic, Alexander
机构
[1] Peter MacCallum Canc Ctr, Dept Pathol, Mol Pathol Res & Dev Lab, Melbourne, Vic 8006, Australia
[2] Li Ka Shing Ctr, Canc Res UK Cambridge Res Inst, Funct Genom Drug Resistance Lab, Cambridge CB2 0RE, England
[3] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia
[4] Peter MacCallum Canc Ctr, Ian Potter Ctr Genom & Predict Med, Melbourne, Vic 8006, Australia
[5] Univ Cambridge, MRC, Res Ctr, Cambridge CB2 2XZ, England
[6] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia
[7] Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia
关键词
D O I
10.1186/1471-2407-7-168
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: p53 is commonly inactivated by mutations in the DNA-binding domain in a wide range of cancers. As mutant p53 often influences response to therapy, effective and rapid methods to scan for mutations in TP53 are likely to be of clinical value. We therefore evaluated the use of high resolution melting (HRM) as a rapid mutation scanning tool for TP53 in tumour samples. Methods: We designed PCR amplicons for HRM mutation scanning of TP53 exons 5 to 8 and tested them with DNA from cell lines hemizygous or homozygous for known mutations. We assessed the sensitivity of each PCR amplicon using dilutions of cell line DNA in normal wild-type DNA. We then performed a blinded assessment on ovarian tumour DNA samples that had been previously sequenced for mutations in TP53 to assess the sensitivity and positive predictive value of the HRM technique. We also performed HRM analysis on breast tumour DNA samples with unknown TP53 mutation status. Results: One cell line mutation was not readily observed when exon 5 was amplified. As exon 5 contained multiple melting domains, we divided the exon into two amplicons for further screening. Sequence changes were also introduced into some of the primers to improve the melting characteristics of the amplicon. Aberrant HRM curves indicative of TP53 mutations were observed for each of the samples in the ovarian tumour DNA panel. Comparison of the HRM results with the sequencing results revealed that each mutation was detected by HRM in the correct exon. For the breast tumour panel, we detected seven aberrant melt profiles by HRM and subsequent sequencing confirmed the presence of these and no other mutations in the predicted exons. Conclusion: HRM is an effective technique for simple and rapid scanning of TP53 mutations that can markedly reduce the amount of sequencing required in mutational studies of TP53.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Clinical significance of TP53 mutation in myeloma
    Chng, W. J.
    Price-Troska, T.
    Gonzalez-Paz, N.
    Van Wier, S.
    Jacobus, S.
    Blood, E.
    Henderson, K.
    Oken, M.
    Van Ness, B.
    Greipp, P.
    Rajkumar, S. V.
    Fonseca, R.
    LEUKEMIA, 2007, 21 (03) : 582 - 584
  • [22] TP53 mutation in mucinous carcinoma of the breast
    Di Palma, S
    Lavarino, C
    Oggionni, M
    Pilotti, S
    HISTOPATHOLOGY, 1999, 34 (06) : 559 - 560
  • [23] Sarcomas in TP53 germline mutation carriers
    Ognjanovic, Simona
    Olivier, Magali
    Bergemann, Tracy L.
    Hainaut, Pierre
    CANCER RESEARCH, 2011, 71
  • [24] TP53 mutation is rare in primary myelofibrosis
    Greaves, Wesley O.
    Verma, Shalini
    Bisrat, Tigist
    Strati, Paolo
    Rahimi, Hamed
    Paladugu, Abhaya V.
    Luthra, Rajyalakshmi
    Patel, Keyur P.
    Medeiros, L. Jeff Rey
    Yao, Hui
    Pierce, Sherry
    Bueso-Ramos, Carlos E.
    Verstovsek, Srdan
    LEUKEMIA & LYMPHOMA, 2013, 54 (07) : 1552 - 1552
  • [25] Clinical significance of TP53 mutation in myeloma
    W J Chng
    T Price-Troska
    N Gonzalez-Paz
    S Van Wier
    S Jacobus
    E Blood
    K Henderson
    M Oken
    B Van Ness
    P Greipp
    S V Rajkumar
    R Fonseca
    Leukemia, 2007, 21 : 582 - 584
  • [26] Harmonized microarray/mutation scanning analysis of TP53 mutations in undissected colorectal tumors
    Favis, R
    Huang, JM
    Gerry, NR
    Culliford, A
    Paty, P
    Soussi, T
    Barany, F
    HUMAN MUTATION, 2004, 24 (01) : 63 - 75
  • [27] Mutation scanning using high-resolution melting
    Taylor, Claire F.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2009, 37 : 433 - 437
  • [28] MUT-TP53: A versatile matrix for TP53 mutation verification and publication
    Soussi, Thierry
    Rubio-Nevado, Jean Michel
    Ishioka, Chikashi
    HUMAN MUTATION, 2006, 27 (11) : 1151 - 1154
  • [29] Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations
    Soussi, T
    Kato, S
    Levy, PP
    Ishioka, C
    HUMAN MUTATION, 2005, 25 (01) : 6 - 17
  • [30] TP53 Promoter Methylation in Primary Glioblastoma: Relationship with TP53 mRNA and Protein Expression and Mutation Status
    Jesionek-Kupnicka, Dorota
    Szybka, Malgorzata
    Malachowska, Beata
    Fendler, Wojciech
    Potemski, Piotr
    Piaskowski, Sylwester
    Jaskolski, Dariusz
    Papierz, Wielislaw
    Skowronski, Wieslaw
    Och, Waldemar
    Kordek, Radzislaw
    Zawlik, Izabela
    DNA AND CELL BIOLOGY, 2014, 33 (04) : 217 - 226